7Baggers
 Sagimet Biosciences stock price target raised to $35 by Citizens  Investing.com South Africa Fri, 14 Nov 2025 23:24:24 GMT
 published on: 2025-11-14 13:47:46  newser.com Fri, 14 Nov 2025 19:47:46 GMT
 published on: 2025-11-10 04:34:15  newser.com Fri, 14 Nov 2025 19:47:46 GMT
 Sagimet Biosciences Reports Q3 2025 Financial Results  TipRanks Fri, 14 Nov 2025 05:28:54 GMT
 Sagimet Biosciences reports Q3 EPS (40c), consensus (39c)  TipRanks Thu, 13 Nov 2025 22:21:15 GMT
 Sagimet Biosciences Reports Q3 Results and Updates  TipRanks Thu, 13 Nov 2025 13:11:25 GMT
 Sagimet Biosciences Q3 net loss narrows as costs drop  TradingView Thu, 13 Nov 2025 12:41:10 GMT
 Sagimet Biosciences Inc. SEC 10-Q Report  TradingView Thu, 13 Nov 2025 12:33:00 GMT
 MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD  Citeline News & Insights Tue, 11 Nov 2025 22:54:19 GMT
 published on: 2025-11-10 04:34:15  newser.com Mon, 10 Nov 2025 10:34:15 GMT

Sagimet Biosciences Inc.
(NASDAQ:SGMT) 

SGMT stock logo

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors to treat non-alcoholic steatohepatitis, acne, and various cancers. The company's lead drug candidate is Denifanstat, a fatty acid synthase inhibitor for the treatm...

Founded: 2006
Sector: TECHNOLOGY
Industry: GENERAL

Share this website to your friends